RxDoctor Payments Data

Saleh Al Ameen, MD

Family Medicine · Dearborn, MINPI 1265829873

Payments from drug & device makers

$3,724in general payments, 2019–2025

Across 84 payments — averaging $44.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Exact Sciences$160
  • Novo Nordisk$159
  • Pfizer$120
  • AbbVie$48
  • Hologic Sales And Service, LLC$40
  • plus $213 from 10 others

What the payments were for

  • Speaking & faculty fees$1,60043%
  • Food & beverage$2,10456%
  • Other$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,724 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$159,475
Medicare patients
442
Services billed
1,683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$97,916
EliquisApixaban77$87,658
FarxigaDapagliflozin Propanediol90$87,062
Trelegy ElliptaFluticasone/Umeclidin/Vilanter94$63,405
JardianceEmpagliflozin45$51,160
RybelsusSemaglutide14$36,287
TrulicityDulaglutide29$29,132
TradjentaLinagliptin25$24,158
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$22,036
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$19,658
Bydureon BciseExenatide Microspheres20$17,305
LinzessLinaclotide24$16,295
MounjaroTirzepatide15$16,053
Lantus SolostarInsulin Glargine,hum.Rec.Anlog83$12,790
Xigduo XrDapaglifloz Propaned/Metformin14$9,781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$159$134,203113 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,983$106,720112 claims
PfizerEliquis$120$87,65877 claims
Boehringer IngelheimJardiance, Tradjenta$21$75,31870 claims
GSKTrelegy Ellipta$23$63,40594 claims
Lilly USA, LLCTrulicity, Mounjaro$13$45,18544 claims
AbbVieLinzess$48$16,29524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →